DNA Genotek, a Subsidiary of OraSure, Launches HEMAcollect™●PROTEIN for Proteomic Research
Reuters
Jul 10
DNA Genotek, a Subsidiary of OraSure, Launches HEMAcollect™●PROTEIN for Proteomic Research
OraSure Technologies, Inc. has launched a new product through its subsidiary, DNA Genotek, to advance proteomic research. The product, HEMAcollect™●PROTEIN, is an evacuated blood collection tube designed to preserve and stabilize plasma proteins in whole blood for up to seven days. This innovation, intended for research use, aims to overcome limitations of conventional blood collection tubes by facilitating storage and transport of blood samples at ambient temperature. This development promises to deliver operational and financial efficiencies to proteomic researchers and enhance the quality of data generated. The device is compatible with various proteomic technologies, including mass spectrometry and immunoassays, and is applicable in multiple research areas such as oncology and neurology.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OraSure Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9491972-en) on July 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.